Why Is Immuneering Stock Trading Higher On Tuesday?

On Tuesday, Immuneering Corporation IMRX revealed data updates from three pancreatic cancer arms of its ongoing Phase 2a trial of lead program IMM-1-104 and plans to expand the Phase 2a trial to include three additional combination arms.

Updated data from the Phase 2a arm of IMM-1-104 with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer shows:

• As of December 5, 2024, three patients achieved complete or partial responses for an overall response rate of 43% (3/7) and a disease control rate of 86% (6/7). Four patients remain on treatment.
• The Phase 3 MPACT study established benchmarks for gemcitabine/nab-paclitaxel alone in first-line pancreatic cancer patients, which included 1 Complete Response (CR) out of 431 patients, a 23% Overall Response Rate, and a 48% Disease Control Rate. 
• Benchmarks for modified (m) Gemcitabine/nab-Paclitaxel, the less intensive regimen utilized in the IMM-1-104 Phase 2 combination arm, include an 18.6% ORR2.
• A favorable tolerability profile was observed for IMM-1-104 combined with modified Gemcitabine/nab-Paclitaxel.

Also Read: Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

Initial Data from Phase 2a Arm of IMM-1-104 with modified FOLFIRINOX in first-line pancreatic cancer:

• All evaluable patients (n=4) experienced target tumor shrinkage and disease control, with one patient achieving a 100% reduction (PR).  
• The combination of IMM-1-104 plus modified FOLFIRINOX (mFFX) was generally well tolerated.
• The company is currently evaluating the 320 mg QD dose of IMM-1-104 in combination with modified FOLFIRINOX.

Initial Data from Phase 2a of IMM-1-104 monotherapy in second-line pancreatic cancer:

• Eleven of the twenty-one evaluable patients treated with IMM-1-104 as monotherapy achieved disease control, including one patient with 67% target lesion shrinkage. Nine patients remain on treatment.
• IMM-1-104 monotherapy was well tolerated in second-line pancreatic cancer patients, suggesting that IMM-1-104 may be highly suitable for both monotherapy and combination therapy.

Immuneering also announced initial pharmacokinetic, pharmacodynamic, and safety data from the Phase 1 portion of the company’s Phase 1/2a trial of IMM-6-415.

The company says further IMM-1-104 Phase 2a data are expected in the second quarter of 2025.

Immuneering says the Phase 2a arm of IMM-1-104 in combination with BRAF inhibitor in melanoma and Phase 2a arms of IMM-1-104 in combination with checkpoint inhibitors in both melanoma and NSCLC are planned for 2025.

Price Action: IMRX stock is up 61.90% at $3.82 during the premarket session at last check Tuesday.

Read Next:

• Optimum-MSGN Standoff Could Pressure MSG Networks’ Finances: Analyst